XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 34 filers reported holding XILIO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,878,645 | -19.5% | 890,353 | 0.0% | 0.00% | – |
| Q2 2023 | $2,332,725 | -17.4% | 890,353 | 0.0% | 0.00% | – |
| Q1 2023 | $2,822,419 | +17.8% | 890,353 | 0.0% | 0.00% | – |
| Q4 2022 | $2,395,049 | -7.7% | 890,353 | -0.1% | 0.00% | – |
| Q3 2022 | $2,595,000 | +112.0% | 891,533 | +112.7% | 0.00% | – |
| Q2 2022 | $1,224,000 | -58.4% | 419,165 | +0.7% | 0.00% | – |
| Q1 2022 | $2,944,000 | -56.6% | 416,393 | -1.8% | 0.00% | – |
| Q4 2021 | $6,788,000 | – | 424,224 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $10,191,000 | 10.46% |
| AJU IB Investment Co., Ltd. | 667,742 | $4,721,000 | 7.29% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $19,509,000 | 2.47% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $19,834,000 | 1.93% |
| Soleus Capital Management, L.P. | 477,495 | $3,376,000 | 0.44% |
| Monashee Investment Management LLC | 163,066 | $1,153,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,078,692 | $14,696,000 | 0.33% |
| RA Capital Management | 2,002,217 | $14,156,000 | 0.31% |
| HARVARD MANAGEMENT CO INC | 416,059 | $2,942,000 | 0.30% |
| Rock Springs Capital Management LP | 1,191,094 | $8,421,000 | 0.21% |